Research status of the multi-target mechanism and clinical evidence of Xuezhikang in cardiovascular diseases
Luo Hanzhong
Liu Libo
Zhang Yunqi
An Ziyu
Zhang Huan
Zhang Lijun
Tian Jinfan
Song Xiantao
Abstract：Xuezhikang is derived from red yeast rice and contains 13 natural statins(including non-crystalline lovastatin and its analogs)as well as a variety of bioactive components.It synergistically regulates the lipid profile and cholesterol metabolism by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and activating peroxi-some proliferator-activated receptor-related signaling pathways.Meanwhile,it exerts anti-inflammatory,antioxidant and vascular endothelial protective effects in the treatment of cardiovascular diseases by inhibiting nuclear factor-κB activation and promoting the nuclear translocation of nuclear factor E2-related factor 2.Both clinical studies and practice have shown that Xuezhikang can significantly reduce the levels of low-density lipoprotein cholesterol and triglycerides in patients,and alleviate inflammatory status and oxidative stress.It helps to reduce the risk of cardi-ovascular events and improve prognosis in high-risk cardiovascular populations with a history of diabetes,myocardial infarction and other comorbidities.As a monotherapy,it has a definite lipid-lowering effect;it can also be combined with statins or non-statin lipid-lowering drugs(such as ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors)for synergistic lipid-lowering in the treatment of cardiovascular diseases.Based on its good overall tolerability and multi-target action characteristics,Xuezhikang provides a clinically valuable therapeutic option for the primary and secondary prevention of cardiovascular diseases.
Keywords：Cardiovascular diseasesXuezhikangLipid metabolismInflammationClinical application
Publication Date：2026-04-18
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 598-602 )